Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $83.30 | Total: $416.50 |
| 1 | 10 | $70.56 | Total: $705.60 |
| 1 | 25 | $59.78 | Total: $1,494.50 |
| 1 | 50 | $50.96 | Total: $2,548.00 |
| 1 | 100 | $44.10 | Total: $4,410.00 |
Overview
Vorolanib (X-82) is an orally active VEGFRPDGFR dual inhibitor.
Chemical Properties
| Molecular Formula | C23H26FN5O3 |
| Molecular Weight | 439.48 |
| CAS Numbers | 1013920-15-4 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CN(C)C(=O)N1CC[C@@H](C1)NC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc23)c1C |
Storage and Handling
0C Short Term, -20C Long Term
References
Bendell JC, et al. Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors. Oncologist. 2019 Apr;24[4] 455-e121.